23446

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER ACTION	as well	see Form PCT/ISA/220 as, where applicable, item 5 below.
032219WOTM International application No.	International filing date (day/mont	h/vear)	(Earliest) Priority Date (day/month/year)
			16/07/2003
PCT/HU2004/000077	16/07/2004 16/07/2003		16/07/2003
Applicant			•
RICHTER GEDEON VEGYESZETI	CVAD DT		
RICHTER GEDEON VEGYESZETT	GIAR RI.		
This International Search Report has bee according to Article 18. A copy is being tra	n prepared by this International Sea ansmitted to the International Burea	rching Autl u.	hority and is transmitted to the applicant
This International Search Report consists	of a total ofs	eets.	
X It is also accompanied by	a copy of each prior art document	cited in this	report.
Basis of the report a. With regard to the language, the language in which it was filed, un	international search was carried ou less otherwise indicated under this	t on the ba item.	isis of the international application in the
The international this Authority (Ru	search was carried out on the basi ile 23.1(b)).	s of a trans	lation of the international application furnished to
b. With regard to any nucle	otide and/or amino acid sequenc	e disclosed	d in the international application, see Box No. I.
2. Certain claims were fou	ind unsearchable (See Box II).		
3. Unity of invention is lac	cking (see Box III).		
 With regard to the title, 			
	ubmitted by the applicant.		
the text has been establi	shed by this Authority to read as fol	lows:	
5. With regard to the abstract,			
	submitted by the applicant.		War the second in Box No. IV. The applicant
the text has been establ may, within one month fi	ished, according to Rule 38.2(b), by rom the date of mailing of this interr	this Authonational sea	ority as it appears in Box No. IV. The applicant arch report, submit comments to this Authority.
6. With regards to the drawings,			
a. the figure of the drawings to be		e No	
as suggested by		م دامالمط	uggest a figure
	his Authority, because the applican		
	his Authority, because this figure be	etter charac	Menzes the inventorit.
b. X none of the figures is to	be published with the abstract.		
Form PCT/ISA/210 (first sheet) (January 20	004)		

INTERNATIONAL SEARCH REPORT

International Application No PCT/HU2004/000077

A. CLASSIF IPC 7	FICATION OF SUBJECT MATTER A61K31/42 C07D231/12		
According to	International Patent Classification (IPC) or to both national classific	cation and IPC	
	SEARCHED		
	cumentation searched (classification system followed by classificat	ion symbols)	
	ion searched other than minimum documentation to the extent that		
	ata base consulted during the international search (name of data baternal, WPI Data, BEILSTEIN Data, C)
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the re-	elevant passages	Relevant to claim No.
X	JOSH J. YUAN ET AL.: "Dispositi specific cyclooxygenase-2 inhibi valdecoxib, in human" DRUG METABOLISM AND DISPOSITION, vol. 30, no. 9, 2002, pages 1013 XP002311618	1,2,6,7	
Υ	cited in the application abstract; figure 5		1-7, 14-21
	page 1018, column 2, paragraph 2		
		-/	
X Furt	her documents are listed in the continuation of box C.	Patent family members are listed	in annex.
° Special ca 'A' docume consider 'E' earlier filing of the citation of the country of the citation of the cita	ategories of cited documents: ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international	'T' later document published after the int or priority date and not in conflict with cited to understand the principle or the invention 'X' document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the decannot be considered to involve an indocument is combined with one or ments, such combination being obvidin the art. '&' document member of the same paten.	n the application but secony underlying the claimed invention to be considered to occurrent is taken alone claimed invention eventive step when the lore other such docupous to a person skilled
	actual completion of the international search	Date of mailing of the international se	arch report
	21 December 2004	20/01/2005	
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk	Authorized officer	
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Molina de Alba, o]

1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/HU2004/000077

ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Citation of document, with indication, where appropriate, of the relevant passages	Ticlevan to dan Ticle
JOHN J. TALLEY ET AL.: "4-'5-Methyl-3-phenylisoxazol-4-yl!-benzen esulfonamide, Valdecoxib: A potent and selective inhibitor of COX-2" J.MED.CHEM., vol. 43, 2000, pages 775-777, XP002311619 page 776, column 2, paragraph 2 - paragraph 3; compounds 2,3	1-21
HERBERT T. NAGASAWA ET AL.: "Carbethoxylating agents as inhibitors of aldehyde dehydrogenase" J.MED.CHEM., vol. 38, 1995, pages 1872-1876, XP002311620 page 1875, column 1, last paragraph	8-13
MAURICE L. MOORE ET AL.: "Substituted sulfanilamides. III. N4-Acyl-N1-hydroxy derivatives" J.AM.CHEM.SOC., vol. 62, 1940, pages 2097-2099, XP002311621 page 2098, column 1, paragraph 2 - paragraph 3	8-13
JI Y. ZHANG ET AL.: "Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice" DRUG METABOLISME AND DISPOSITION, vol. 31, no. 4, April 2003 (2003-04), pages 491-501, XP002311622 page 501, column 1, last paragraph - column 2, paragraph 1; figure 8	1-21
DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SARAPA, NENAD ET AL: "Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization" XP002311623 retrieved from STN Database accession no. 2003:753917 abstract & JOURNAL OF CLINICAL PHARMACOLOGY, 43(9), 974-982 CODEN: JCPCBR; ISSN: 0091-2700, 2003,	14-21
	Citation of document, with indication, where appropriate, of the relevant passages JOHN J. TALLEY ET AL.: "4-'5-Methyl-3-phenylisoxazol-4-yl!-benzen esulfonamide, Valdecoxib: A potent and selective inhibitor of COX-2" J.MED.CHEM., vol. 43, 2000, pages 775-777, XP002311619 page 776, column 2, paragraph 2 - paragraph 3; compounds 2,3 HERBERT T. NAGASAWA ET AL.: "Carbethoxylating agents as inhibitors of aldehyde dehydrogenase" J.MED.CHEM., vol. 38, 1995, pages 1872-1876, XP002311620 page 1875, column 1, last paragraph MAURICE L. MOORE ET AL.: "Substituted sulfanilamides. III. N4-Acyl-N1-hydroxy derivatives" J.AM.CHEM.SOC., vol. 62, 1940, pages 2097-2099, XP002311621 page 2098, column 1, paragraph 2 - paragraph 3 JI Y. ZHANG ET AL.: "Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice" DRUG METABOLISME AND DISPOSITION, vol. 31, no. 4, April 2003 (2003-04), pages 491-501, XP002311622 page 501, column 1, last paragraph - column 2, paragraph 1; figure 8 DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SARAPA, NENAD ET AL: "Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization" XP002311623 retrieved from STN Database accession no. 2003:753917 abstract & JOURNAL OF CLINICAL PHARMACOLOGY, 43(9), 974-982 CODEN: JCPCBR; ISSN:

1